

```
[et_pb_section bb_built="1" fullwidth="on" specialty="off" transparent_background="off"
allow_player_pause="off" inner_shadow="off" parallax="off" parallax_method="off"
make_fullwidth="off" use_custom_width="off" width_unit="on" make_equal="off"
use_custom_gutter="off"] [et_pb_fullwidth_header background_layout="light"
text_orientation="left" header_fullscreen="off" header_scroll_down="off"
background_url="http://www.flatleydiscoverylab.com/wp-content/uploads/2017/05/AdobeStock_112123671_Preview.jpeg" background_color="#f5f1e3" content_orientation="center"
image_orientation="center" custom_button_one="off" button_one_letter_spacing="0"
button_one_icon_placement="right" button_one_letter_spacing_hover="0"
custom_button_two="off" button_two_letter_spacing="0"
button_two_icon_placement="right" button_two_letter_spacing_hover="0"
custom_css_main_element="padding: 120px 0px;"
background_overlay_color="rgba(245,241,227,0)" module_class="gradient-overlay"
_builder_version="3.0.62"
background_image="http://www.flatleydiscoverylab.com/wp-content/uploads/2017/07/FDL34.jpg" /] [et_pb_section bb_built="1" fullwidth="off" specialty="on"
parallax_method="off" parallax_method_1="off" parallax_method_2="off"
module_class_2="sidebar" _builder_version="3.0.62" background_position_1="top_left"
background_repeat_1="no-repeat" background_position_2="top_left"
background_repeat_2="no-repeat" custom_padding="25px|||"
padding_top_2="0px"] [et_pb_column type="3_4" specialty_columns="3"] [et_pb_row_inner
admin_label="Row" _builder_version="3.0.62" background_position_1="top_left"
background_repeat_1="no-repeat" custom_css_main_element="border-bottom: 2px solid #f5f1e3;" ] [et_pb_column_inner type="4_4" saved_specialty_column_type="3_4"] [et_pb_text
admin_label="Heading" _builder_version="3.0.62" background_layout="light"
text_orientation="left" border_style="solid" saved_tabs="all"]
```

## FDLCombo

```
[/et_pb_text] [et_pb_blurb admin_label="FDL169 a CFTR Corrector"
_builder_version="3.0.62" title="FDL169-2018-010 Part 4: A study of a CFTR corrector and
potentiator combination in people with cystic fibrosis (FDL169/176)" url="/fdlcombo/"
url_new_window="off" use_icon="off" use_circle="off" use_circle_border="off"
icon_placement="top" use_icon_font_size="off" background_layout="light"
border_style="solid" animation="top"]
```

This is a Four-Part, Phase 1-2, Drug-Drug Interaction Study to Assess the Safety, Tolerability, and Pharmacokinetic (PK) Profile of concomitant FDL176 (a potentiator) and FDL169 (a 1st site corrector) in Healthy subjects (Parts 1-3) and Cystic Fibrosis (CF) Subjects (Part 4).

Part 1 dosing included FDL169 for 4 weeks with the 3rd and 4th week following a single dose FDL176. Part 2 dosing included FDL176 for 3 weeks with the 3rd week following concomitant FDL169 for a total of seven doses. Part 3 dosing included 28 days of concomitant FDL169 and FDL176. Part 4 is a randomized, double-blind, placebo-controlled, 28-day concomitant dosing of FDL169 and FDL 176 in CF subjects.

Enrollment for Part 4 of this study is currently ongoing in the U.K. For more information please refer to the [Celerion website](#) and [clinicaltrials.gov](#).

## **Requirements for participation in the study**

Healthy Subjects:

- Body mass index (BMI) between 19 and 30 kg/m<sup>2</sup>
- Healthy as determined by the PI or delegate, based upon a medical evaluation including medical history, physical examination, laboratory tests and ECG.

Cystic Fibrosis Subjects:

- Males and females aged 18 years and older
- A diagnosis of cystic fibrosis
- Be 18 years of age or older
- Have an FEV<sub>1</sub> 40 - 90% predicted
- No respiratory tract infection, pulmonary exacerbation, or changes in therapy for pulmonary disease 4 weeks prior to dosing
- No treatment with ivacaftor or lumacaftor 4 weeks prior to dosing

Additional information on this trial is available at [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

```
[/et_pb_blurb][et_pb_button button_url="/fdlcombo " url_new_window="off"
button_text="Learn More" button_alignment="right" background_layout="dark"
custom_button="on" button_bg_color="#63ccca" button_border_color="#63ccca"
button_letter_spacing="0" button_icon_color="#ffffff" button_icon_placement="right"
button_letter_spacing_hover="0" button_border_radius="0" saved_tabs="all"
```

```
_builder_version="3.0.62" disabled="on" disabled_on="on|on|on"
/[/et_pb_column_inner]/[/et_pb_row_inner]/[/et_pb_row_inner
admin_label="Row"][/et_pb_column_inner type="4_4"
saved_specialty_column_type="3_4"][/et_pb_image _builder_version="3.0.62"
src="http://www.flatleydiscoverylab.com/wp-content/uploads/2017/05/FDL13-resized.jpg"
show_in_lightbox="off" url_new_window="off" use_overlay="off" sticky="off"
align="center" always_center_on_mobile="on" border_style="solid" force_fullwidth="off"
animation="off" /[/et_pb_column_inner]/[/et_pb_row_inner]/[/et_pb_column]/[/et_pb_column
type="1_4"][/et_pb_sidebar _builder_version="3.0.62" saved_tabs="all"
area="et_pb_widget_area_2" orientation="right" background_layout="light" /[/et_pb_button
admin_label="Make a Difference Button" button_url="/volunteer-opportunities/"
url_new_window="off" button_text="Make a Difference" button_alignment="center"
background_layout="dark" custom_button="on" button_bg_color="#63ccca"
button_border_color="#63ccca" button_letter_spacing="0" button_icon="%%141%%"
button_icon_color="#ffffff" button_icon_placement="right"
button_letter_spacing_hover="0" custom_css_main_element="width: 100%;"
button_border_radius="0" saved_tabs="all" _builder_version="3.0.62"
/[/et_pb_column]/[/et_pb_section]
```